Current Report Filing (8-k)
September 07 2022 - 4:16PM
Edgar (US Regulatory)
0001522767
false
0001522767
2022-09-07
2022-09-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 7, 2022
MARIMED
INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
0-54433 |
|
27-4672745 |
| (State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
| of incorporation) |
|
File Number) |
|
Identification No.) |
| 10
Oceana Way, Norwood, Massachusetts |
|
02062 |
| (Address of principal executive
offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (617) 795-5140
| |
| (Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None.
| Title
of each class |
|
Ticker
symbol(s) |
|
Name
of each exchange on which registered |
| Not Applicable. |
|
Not Applicable. |
|
Not Applicable. |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02. | Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
(c)
and (e): Effective September 7, 2022 (the “Effective Date”), MariMed Inc. (the “Company”) promoted
Jon Levine, Chief Administrative Officer of the Company, to President of the Company replacing Robert Fireman in that position (the “Promotion”).
Mr. Fireman will continue in his roles as the Company’s Chief Executive Officer and Chairman of the Board.
On
the Effective Date, in connection and consistent with Mr. Levine’s Promotion to the position of President of the Company,
Mr. Levine’s employment agreement with the Company was amended to change his title to President, and to reflect responsibilities
and duties commensurate with that position. A copy of the form of the amendment to his employment agreement is attached as Exhibit 10.1
hereto.
On
the Effective Date, the Company issued a press release announcing the Promotion, a copy of which is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
| Item 9.01. | Financial
Statements and Exhibits. |
(d)
Exhibits
**********
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
MARIMED INC. |
| |
|
|
| Dated:
September 7, 2022 |
By: |
/s/
Susan Villare |
| |
|
Susan Villare, Chief Financial
Officer |
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Oct 2024 to Nov 2024
MariMed (QX) (USOTC:MRMD)
Historical Stock Chart
From Nov 2023 to Nov 2024
